KMT2A rearrangement MLL is a questionable disease in the field of blood tumours, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardized clinical treatment are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging checks, laboratory tests and pathological activation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule according to the changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of MLL re-arranged with acute myeloid leukemia KMT2A. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.